PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tadalafil - Penile rehabilitation

PAD Profile : Tadalafil - Penile rehabilitation

Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence
Brand Names Include :
Cialis

Traffic Light Status

Status 1 of 2.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
2.5mg tablets are non-formulary (very costly)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Non Formulary
Important
Formulations :
  • 2.5mg ONCE DAILY
Important Information :
2.5mg tablets are non-formulary (very costly)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC has updated the recommendation for the use of tadalafil for penile rehabilitation as follows:

Tadalafil "as required" (10mg and 20mg) has a Blue traffic light status and may be prescribed in primary care on recommendation from a specialist.

Tadalafil daily dosing (5mg) has a Blue traffic light status and may be prescribed in primary care on recommendation from a specialist.

Tadalafil 2.5mg daily is non-formulary (very costly).

Use in combination with any other oral / non-oral treatments for erectile dysfunction is not supported

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More